8-K: Charlotte's Web Reports Q2 Growth, Cuts Costs

Charlotte's Web Holdings, Inc. announced its second consecutive quarter of year-over-year revenue growth for Q2 2025, driven by new product innovations and significant cost reductions.

Summary

• Consolidated net revenue for Q2 2025 increased 4.2% year-over-year to $12.8 million, up from $12.3 million in Q2 2024.
• Gross profit significantly improved to $6.0 million (46.8% of revenue) in Q2 2025, compared to $2.6 million (21.0% of revenue) in Q2 2024.
• Selling, general, and administrative (SG&A) expenses decreased 31.7% year-over-year to $10.1 million in Q2 2025.
• Net loss for Q2 2025 was reduced to $6.3 million, or $(0.04) per share, a significant improvement from a net loss of $11.1 million, or $(0.07) per share, in Q2 2024.
• Adjusted EBITDA improved by 30.8% to $(3.6) million in Q2 2025, compared to $(5.2) million in Q2 2024.
• Cash burn for the first half of 2025 was reduced by 52.0% year-over-year.
• The company commenced in-house production of Brightside gummies, anticipating approximately $3 million in annualized cost savings from internalization efforts.
• Additional expense reduction measures implemented post-quarter are expected to reduce annualized costs by more than $6 million in 2026, totaling approximately $9 million in annualized savings combined with in-house manufacturing.

Sentiment

Score: 7

Explanation: The sentiment is positive due to significant improvements in key financial metrics, including revenue growth, reduced losses, and substantial cost savings. The company is demonstrating a clear turnaround strategy with successful new product launches and a path towards positive cash flow. While still operating at a net loss, the trajectory is strongly positive.

Positives

• Achieved second consecutive quarter of year-over-year revenue growth since 2021, with Q2 2025 revenue at $12.8 million, up 4.2% from Q2 2024.
• Gross profit increased substantially to $6.0 million in Q2 2025 from $2.6 million in Q2 2024, reflecting improved profitability.
• Selling, general, and administrative (SG&A) expenses were reduced by 31.7% year-over-year to $10.1 million, demonstrating effective cost optimization.
• Net loss significantly narrowed to $6.3 million in Q2 2025 from $11.1 million in Q2 2024.
• Adjusted EBITDA improved by 30.8% to $(3.6) million, indicating progress towards profitability.
• Cash burn for the first half of 2025 was reduced by 52.0% year-over-year.
• Successful launch and rapid uptake of Brightside hemp-derived THC gummies, exceeding internal forecasts.
• Expanded product portfolio into high-growth categories with CBG Focus & Attention Gummies and functional mushroom gummies.
• Commenced in-house gummy production, expected to yield $3 million in annualized cost savings and improve margins.
• Implemented additional expense reduction measures post-quarter, targeting over $6 million in annualized savings for 2026, contributing to a total of approximately $9 million in annualized cost reductions.

Negatives

• The company continues to operate at a net loss of $6.3 million in Q2 2025.
• Adjusted EBITDA remains negative at $(3.6) million.
• Cash and cash equivalents decreased to $15.3 million as of June 30, 2025, from $22.6 million at December 31, 2024.
• Adjusted gross margin percentage slightly decreased to 46.6% in Q2 2025 from 52.2% in Q2 2024 (excluding inventory provisions), due to insourcing startup costs, zero-margin DeFloria extract sales, and promotional activities.

Risks

• Supply and distribution chain disruptions.
• Fluctuations in the market for the company's products.
• Revenue volatility.
• Changes in regulatory frameworks for hemp-derived products.
• Loss of key customers and retail partners.
• Challenges in retaining and attracting qualified talent.
• Competition from other products in the market.
• Share price volatility.
• Loss of proprietary information.
• Challenges with product acceptance by consumers.
• Functionality and security of internet and system infrastructure.
• Availability of adequate capital to fund operations and business plans.
• Crop risks affecting raw material supply.
• Broader economic and political considerations.

Future Outlook

The company remains confident in its ability to execute and deliver on its 2025 outlook, anticipating continued operational momentum and strong early traction across new product categories. It expects to transition additional gummy SKUs to in-house production in the second half of 2025 and is evaluating further transitions in topical production for 2026. Management projects that disciplined cost management, expanding gross margins from scaling in-house production, and modest revenue growth will position the company to approach positive cash flow. The company also anticipates a more favorable evolving regulatory landscape for hemp-derived products, with potential for clear federal frameworks for CBD as dietary supplements and food ingredients, which is expected to consolidate the industry in favor of established brands.

Management Comments

• "Q2 marked another step forward in our turnaround as Charlotte's Web again delivered both sequential and year-over-year growth, demonstrating continued progress in revenue and strategic execution across omnichannel, innovation, and cost structure." Bill Morachnick, CEO
• "We successfully commenced in-house production of our new Brightside gummies and extended our omnichannel reach while achieving early success with our new product categories. With operational momentum building and strong early traction across new product categories, we remain confident in our ability to execute and deliver on our 2025 outlook." Bill Morachnick, CEO
• "Our revenue growth was accompanied by rigorous SG&A discipline that reduced second quarter expenses 31.7% year-over-year. Post-quarter, we've implemented additional measures to reduce our annualized run rate by more than $6 million in 2026. Combined with our transition to in-house manufacturing, which will benefit profit margins over time, this disciplined cost management and modest revenue growth positions us to approach positive cash flow." Erika Lind, CFO
• "Q2 demonstrated continued year-over-year progress in our financial transformation. For the first half of 2025, we've reduced our cash burn by 52.0% year-over-year while returning to growth. Our cash and working capital has us well-positioned to complete our return to positive cash flow. The combination of our dramatically lower operating expense base, expanding gross margins as we scale in-house production, and modest revenue growth requirements creates multiple paths to positive cash flow." Erika Lind, CFO

Industry Context

The company operates within the evolving botanical wellness and hemp extract market, which includes CBD, minor cannabinoids like CBN and CBG, and functional mushrooms. Its expansion into CBG and functional mushrooms aligns with growing consumer demand for natural cognitive enhancement and plant-based alternatives to synthetic nootropics. The industry is also facing a dynamic regulatory environment, with the company actively working with coalitions to advance federal regulation for hemp-derived products, anticipating that clear FDA pathways for CBD as dietary supplements and food ingredients will consolidate the market in favor of established, quality-focused brands. The company's collaboration on DeFloria's clinical trials positions it in the multi-billion-dollar autism spectrum disorder treatment market, diversifying its long-term revenue opportunities beyond direct consumer sales of hemp products.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry benchmarking. The focus is on internal operational improvements and market positioning within the broader botanical wellness and hemp extract categories.

Stakeholder Impact

• Shareholders: The significant reduction in net loss and cash burn, coupled with revenue growth and cost optimization, suggests an improving financial outlook and potential for future profitability, which could positively impact shareholder value.
• Customers: New product innovations like Brightside THC gummies, CBG Focus & Attention Gummies, and functional mushroom gummies, along with expanded digital platform access, offer a broader range of wellness solutions.
• Employees: The reduction in personnel costs and ongoing cost optimization strategies may imply workforce adjustments, though the filing emphasizes efficiency improvements.

Next Steps

• Transition additional gummy SKUs to in-house production in the second half of 2025.
• Evaluate further transitions in topical production for 2026.
• Continue working with industry coalitions to advance comprehensive federal regulation of hemp-derived products.
• DeFloria, Inc. will continue Phase 2 clinical trials for AJA001 Oral Solution to treat irritability associated with autism spectrum disorder (ASD).

Key Dates

Recommendation

The company is demonstrating a strong turnaround with consistent year-over-year revenue growth, significant reductions in operating expenses and net losses, and a substantial decrease in cash burn. Strategic initiatives like in-house manufacturing and new product diversification are yielding positive results and are expected to drive further margin expansion and cost savings. While still unprofitable, the clear trajectory towards positive cash flow, coupled with a strengthening market position in a potentially regulated industry, makes this an attractive 'buy' for investors looking for a growth story with improving fundamentals.

Keywords

CBD, Hemp, Cannabidiol, Botanical Wellness, Cannabinoids, THC Gummies, Functional Mushrooms, Nootropics, Consumer Packaged Goods, SEC Filing, Earnings Report, Cost Optimization, Omnichannel Sales